AI Weekly Malaysia

A satirical blog post (dated Sept 28, 2026, ~6 min read) argues LinkedIn's feed is dominated by near-identical computer-vision demo posts — hand-tracking webcam tricks and a pothole-detection project — which the author says are either tutorial-derived or vibecoded, and which in the pothole case 'is not sending it to anything.' As a counter-move, the author describes building a 'YOLO Post Detector' aimed at the '🚀 Excited to announce...' style of post. The Hacker News thread drew 270 points and 222 comments.

Why: If you are building a portfolio or launch demo to post publicly, this piece gives a concrete differentiation test rather than a vibe check: does the output go somewhere? The author singles out the pothole detector because it only displays a detection locally instead of feeding an API or downstream action — the same criticism would apply to any hand-tracking or object-detection demo that ends at a bounding box on screen. Decide now whether your next demo has a consumer of its output (an alert, a ticket, a dashboard, a dataset) or is just a webcam effect, because the audience this piece represents can no longer tell them apart. Note: the text contains no Malaysian or Southeast Asian angle, so there is no local policy, funding, or infrastructure impact to draw from it.

Neko Health, the Swedish body-scan startup co-founded by Spotify's David Ek and Hjalmar Nilsonne, has opened in New York after raising nearly $1 billion and building a global waitlist it says tops 300,000 people. The one-hour scan screens blood, skin, and metabolism using computer vision, and is sold direct to consumers at $500 — not covered by insurance, but positioned as HSA-eligible. Investor Farooq Abbasi of Preface Ventures says his blood panel went from 15 biomarkers in an earlier generation to 55 now, and that the company is eyeing wider U.S. expansion while still facing scaling and regulatory approval work.

Why: There is no direct action here for Malaysian developers or founders — this is a U.S. consumer health expansion, not tooling, infrastructure, or policy that touches your stack. The one transferable detail is the pricing model: a $500 cash-pay, insurance-bypassing screening product with a 300,000-person waitlist, which is a data point if you are building any direct-to-consumer health or diagnostics product in Malaysia's private healthcare market. Otherwise treat it as context, not a decision trigger.